AFLAC Inc. stock holds firm as earnings strength supports valuation

AFLAC Inc. stock remains supported by solid recent earnings and robust profitability metrics, even as valuation screens as slightly rich versus fundamentals. For investors, the combination of strong margins and steady demand in supplemental insurance is key.

AFLAC Inc. stock (ISIN US0010551028) continues to trade on the back of strong recent earnings, with the insurer benefiting from high profitability in its core supplemental health and life business as of early September 2026. For investors in the US insurance sector, the company remains a large-cap benchmark alongside peers such as Prudential Financial, while European investors mainly access AFLAC via US listings rather than a DACH exchange.

Profitability remains a key support

According to a recent valuation overview compiled in early September 2026, AFLAC carries an equity value of about 58.7 billion USD, supported by annual revenue of around 18.1 billion USD and operating profit of roughly 2,834.0 million USD in the latest reported period. The same overview indicates that AFLAC generates an operating margin in the mid-teens, with an operating margin near 15.6 percent and a net margin of about 11.8 percent in the most recent fiscal year, underlining the high profitability of its insurance portfolio.

The data snapshot also shows that AFLAC stock is currently evaluated as a little over 10 percent overvalued against fair value models, with an overvaluation mark of 11.9 percent as of early September 2026. For investors, this means that the strong earnings and cash flows are largely reflected in the price, and further upside would likely require either higher-than-expected premium growth or additional capital returns.

Recent earnings and valuation metrics

On the earnings side, AFLAC recently reported full-year revenue of about 18.1 billion USD, with operating profit of approximately 2,834.0 million USD and a net margin just under 12 percent, according to a quantitative summary of the most recent completed fiscal year. This combination of scale and profitability leaves the company with a return on equity comfortably in double digits, which helps to justify the current market capitalization of 58.7 billion USD as of early September 2026.

The same quantitative screen dates the current valuation with a fair value framework implying that AFLAC shares trade around 11.9 percent above estimated intrinsic value. In practical terms, this means that while the insurer offers robust fundamentals and resilient margins, the market is already pricing in a continuation of this performance, leaving less room for disappointment in future quarterly reports.

Supplemental insurance as growth driver

AFLAC Inc. generates the bulk of its revenue from supplemental health and life insurance products that are typically sold through employers or directly to individuals, with particularly strong positions in the United States and Japan. These products often cover gaps left by standard health or life policies, which allows AFLAC to earn attractive margins and reduces direct competition with broad-line primary insurers.

In Japan, supplemental health policies focused on cancer and critical illness have historically been a major contributor to premium income, helping AFLAC secure a leading market share in that segment. In the United States, the group has been expanding its voluntary benefits offerings, such as accident, disability and hospital indemnity coverage, where employers increasingly look for flexible benefit structures that can be financed partly by employees.

Stock valuation and investor takeaway

From an investor perspective, the current combination of a 58.7 billion USD market capitalization and mid-teens operating margins suggests that AFLAC stock is priced as a quality income and compounding story rather than a deep value play as of early September 2026. The indication that the stock trades about 11.9 percent above estimated fair value underlines that future earnings reports will need to confirm the current growth and profitability profile to sustain the valuation.

For long-term shareholders, the key questions over the coming quarters will center on the pace of premium growth in core US and Japanese supplemental lines, the development of claims ratios in a more volatile health-care cost environment and potential capital deployment via dividends and share buybacks.

AFLAC Inc. at a glance

• Company: AFLAC Inc.
• ISIN: US0010551028
• Ticker: AFL
• Trading venue: NYSE
• Sector / Industry: Financials / Insurance
• Index membership: S&P 500